OraSure Technologies, Inc.

OSUR

$3.54

-1.26%

2026-09-04 10:37:20 EDT-$0.04

Healthcare

Medical - Instruments & Supplies

NASDAQ

Active Trading

OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions ...

Price Action of OSUR

$3.54

-1.26%-$0.04

High—

Low—

52W High-22.7%

Rel. vol—

Interval

Range64m

Volume—SMA5SMA10

—

OraSure Technologies, Inc. is a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its Diagnostics portfolio includes the InteliSwab rapid tests for COVID-19, OraQuick rapid tests for HIV, ...OraSure Technologies, Inc. is a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its Diagnostics portfolio includes the InteliSwab rapid tests for COVID-19, OraQuick rapid tests for HIV, Hepatitis C, and Ebola, and the OraSure oral fluid collection device. The Molecular Solutions segment offers genomic products under the Oragene and ORAcollect brands, along with microbiome collection solutions and GenoFIND genomics laboratory services. Founded in 1987 as SolarCare, the company is headquartered in Bethlehem, Pennsylvania, and serves a diverse clientele including clinical laboratories, hospitals, public health organizations, and government bodies. With a focus on improving access, quality, and value of healthcare, OraSure continues to innovate in the field of point-of-care diagnostics and sample collection. The company employs around 500 people and is publicly traded on NASDAQ under the symbol OSUR.ExpandCollapse

Founded

1987

Employees

500

CEO

Carrie Eglinton Manner

Full Name

OraSure Technologies, Inc.

Sector

Healthcare

Industry

Medical - Instruments & Supplies

ROE

-14.73%

Market Cap

$0.24B

Current Ratio

8.88

WACC

9.05%

ROIC

-17.42%

Contact Information

https://www.orasure.com

610 882 1820

220 East First Street, Bethlehem, PA 18015

Key Metrics of OSUR

Snapshot

Latest / TTM · 6 periods

Market Cap

$243.80M

ROCE

-15.0%

EV / EBITDA

-2.22x

+3.8% YoY

FCF Yield

-19.5%

-19.5% YoY

Cash Conversion Cycle

203.1d

Current Ratio

8.88

Quick take

TTM —

Positive CCC

Financial Highlights of OSUR

Profitability trend

Latest / TTM · 6 periods

Gross Margin

41.4%

Net Margin

-43.7%

P/E Ratio

-5.19x

n/a

Debt / Equity

0.04

n/a

Current Ratio

8.88

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of OSUR

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.23 · Revenue $31.14M · 1 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.20 · Revenue $32.40M · 1 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-0.66 · Revenue $122.11M · 1 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.21 · Revenue $30.24M · 1 analysts

Recent history

Aug 7, 2026
Q2 FY2026 · Results reported
EPS $0.09 · Revenue $30.64M
View filing
May 8, 2026
Q1 FY2026 · Results reported
EPS $-0.32 · Revenue $27.93M
View filing
Mar 9, 2026
FY2025 · Annual results
EPS $-0.94 · Revenue $115.02M
View filing
Nov 5, 2025
Q3 FY2025 · Results reported
EPS $-0.19 · Revenue $27.09M
View filing
Aug 6, 2025
Q2 FY2025 · Results reported
EPS $-0.26 · Revenue $31.24M
View filing
May 7, 2025
Q1 FY2025 · Results reported
EPS $-0.21 · Revenue $29.93M
View filing

Financial Statements of OSUR

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$115.0M	-38.1%	+9.7%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-68.7M	-252.5%	+127.9%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+41.9%	+2.2%	+16.1%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-59.2%	-434.3%	+121.4%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-59.8%	-469.4%	+125.5%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-53220	-100.2%	+16.6%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	-0.0%	-100.4%	+24.0%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	3.9%	+8.8%	-70.5%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	6.58x	-33.9%	+62.5%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$403.2M	-15.9%	-4.9%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-0.94 vs -0.86	-8.7%	0.09 vs -0.27	+133.3%
Revenue Surprise	$115.0M vs $114.7M	+0.3%	$30.6M vs $29.1M	+5.3%

Insider Transactions of OSUR

Acquisitions (A)

Since May 13, 2026

Disposals (D)

Since May 13, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Jun 26, 2026	Boyd Steven Kyle	director	Common Stock	A	3,666	$4.43
Jun 3, 2026	McMahon Robert W.	director	Common Stock	A	46,106	—
Jun 3, 2026	Gagliano Nancy J	director	Common Stock	A	46,106	—
Jun 3, 2026	Marmora Lelio	director	Common Stock	A	46,106	—
Jun 3, 2026	Kenny John P.	director	Common Stock	A	46,106	—

Earnings Call Transcript of OSUR

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Good day, and thank you for standing by. Welcome to OraSure Technologies Inc. 26 second quarter earnings conference call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press *11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press *11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Michele Anthony, Chief Accounting Officer. Please go ahead. Michele Anthony: Thank you. Good afternoon, and welcome to OraSure Technologies Second Quarter 2026 Earnings Call. Participating in the call today for OTI are Carrie Eglinton Manner, our President and Chief Executive Officer and Kenneth McGrath, our Chief Financial Officer. As a reminder, today's webcast is being recorded. And the recording can be found on our Investor Relations website. Before we begin, you should know that this call may contain certain forward looking statements. Including statements with respect to revenues, expenses, profitability, earnings or loss per share and other financial performance, product development, performance, shipments and markets, business plans, regulatory filings and approvals, expectation and strategies. Actual results could be significantly different. Factors that could affect results are discussed more fully in OTIs SEC filings. Its annual report on Form 10-K for the year ended December 31, 2025 Its quarterly reports on Form 10 Q, and its other SEC filings. Although forward looking statements help to provide more complete information about future prospects, listeners should keep in mind that forward looking statements are based solely on information available to management as of today. OTI undertakes no obligation to update any forward looking statements to reflect events or circumstances after this call. With that, I am pleased to turn the call over to Carrie. Carrie Eglinton Manner: Thanks, Michele, and thanks to everyone for joining us. Today, I will discuss some of the highlights from Q2, and provide updates on our key priorities for 2026. Q2 was another important quarter in OraSure's transformation. We exceeded our revenue guidance expanded gross margin sequentially, advanced our decentralized diagnostics pipeline in rapid tests and sample management solutions, and continue to position the business for sustainable growth and long term shareholder value in the second half of 2026 and beyond. Through our multiyear transformation, we have moved from restructuring and portfolio simplification to execution against a more focused growth strategy. In 2025, we said that 2026 would be a transition year on the path back to growth. Q2 demonstrated that transition beginning to take shape through stronger revenue, improving margins and meaningful …

Leadership Team of OSUR

11 executives

Name	Title	Compensation	Gender	Year Born	Status
Carrie Eglinton Manner	President, Chief Executive Officer & Director	USD 898,040	Female	1975	Active
Kenneth J. McGrath	Chief Financial Officer	USD 577,440	Male	1972	Active
Anne Messing	Chief Commercial Officer	—	Female	—	Active
Karen Davies	Diagnostics R&D & Chief Technologist	—	Female	—	Active
Amy Steigerwalt	Senior Vice President of Human Resources	—	Female	—	Active
Michele Anthony	Senior Vice President, Chief Accounting Officer, Controller & Assistant Secretary	—	Female	1974	Active
Zachary Wert	Senior Vice President of Global Operations	—	Male	—	Active
Jason Michael Plagman	Vice President of Investor Relations	—	Male	—	Active
Rafal Iwasiow	Sample Management Solutions R&D & Chief Scientist	—	Male	—	Active
David A. Rappaport	Senior Vice President of Corporate Development, Strategy & Integration	—	Male	—	Active
Stefano Taucer	General Counsel & Corporate Secretary	—	Male	—	Active

Recent News of OSUR

Seeking Alpha8/6/2026Neutral

OraSure Technologies, Inc. (OSUR) Q2 2026 Earnings Call Transcript

MarketBeat8/6/2026Neutral

OraSure Technologies Q2 Earnings Call Highlights

OraSure Technologies NASDAQ: OSUR reported second-quarter revenue of $30.6 million, exceeding its guidance range and rising 9.7% sequentially, as stronger public-health diagnostics demand and growth in sample-management products supported results.

GlobeNewsWire8/5/2026Neutral

OraSure Announces Second Quarter 2026 Financial Results

BETHLEHEM, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended June 30, 2026.

Globe News Wire8/5/2026Neutral

OraSure Announces Second Quarter 2026 Financial Results

BETHLEHEM, Pa. , Aug. 05, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended June 30, 2026. "Our Q2 results demonstrate continued progress in our return-to-growth trajectory, with revenue of $30.

GlobeNewsWire7/22/2026Neutral

OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th

BETHLEHEM, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after the market closes. It will hold its quarterly conference call to discuss the results beginning at 5 p.m. Eastern Time on that day.

Historical Employee Count of OSUR

Current

500

Change

-0.20%

Minimum

500

Maximum

840

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	500	10-K	Mar 9, 2026	View
Dec 31, 2024	501	10-K	Mar 7, 2025	View
Dec 31, 2023	638	10-K	Mar 11, 2024	View
Dec 31, 2022	840	10-K	Mar 3, 2023	View
Dec 31, 2021	785	10-K	Mar 1, 2022	View

Related stocksMedical - Instruments & Supplies

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

OraSure Technologies, Inc.